Clinical Trials
13 trialsNCT05178043 2024-02-22
GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
Suzhou Kintor Pharmaceutical Inc,
Phase 2 Unknown
NCT05027204 2022-10-13
A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2 Unknown
NCT05468294 2022-07-21
Nivokin
Philogen S.p.A.
Phase 1/2 Unknown
NCT04013334 2022-06-16
MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
Momotaro-Gene Inc.
Phase 2 Unknown
NCT02637531 2022-04-04
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
Infinity Pharmaceuticals, Inc.
Phase 1 Unknown
NCT04521075 2021-08-16
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC
Ella Therapeutics Ltd
Phase 1/2 Unknown
NCT04860076 2021-04-26
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Asylia Diagnostics BV
Unknown
NCT04136470 2020-08-10
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
Ardigen
Unknown
NCT04145232 2020-08-10
AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.
Ardigen
Unknown
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown
NCT03371992 2020-03-27
NO3DEXPL
Nilogen Oncosystems
Phase EARLY_PHASE1 Unknown
NCT04169867 2019-11-20
Polish Microbiome Map
Ardigen
Unknown
NCT03993626 2019-06-21
CAROSELL
Celleron Therapeutics Ltd.
Phase 1/2 Unknown